Incyte Yönetim

Yönetim kriter kontrolleri 3/4

Incyte CEO'su Herve Hoppenot, Jan2014 tarihinde atandı, in görev süresi 10.92 yıldır. in toplam yıllık tazminatı $ 16.66M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler R$ 157.42M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.9 yıl ve 7.9 yıldır.

Anahtar bilgiler

Herve Hoppenot

İcra Kurulu Başkanı

US$16.7m

Toplam tazminat

CEO maaş yüzdesi	7.8%
CEO görev süresi	10.9yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	8.9yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Herve Hoppenot'un ücretlendirmesi Incyte'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$32m
Jun 30 2024	n/a	n/a	US$97m
Mar 31 2024	n/a	n/a	US$745m
Dec 31 2023	US$17m	US$1m	US$598m
Sep 30 2023	n/a	n/a	US$425m
Jun 30 2023	n/a	n/a	US$366m
Mar 31 2023	n/a	n/a	US$324m
Dec 31 2022	US$17m	US$1m	US$341m
Sep 30 2022	n/a	n/a	US$876m
Jun 30 2022	n/a	n/a	US$945m
Mar 31 2022	n/a	n/a	US$933m
Dec 31 2021	US$14m	US$1m	US$949m
Sep 30 2021	n/a	n/a	US$535m
Jun 30 2021	n/a	n/a	US$338m
Mar 31 2021	n/a	n/a	US$478m
Dec 31 2020	US$16m	US$1m	-US$296m
Sep 30 2020	n/a	n/a	-US$335m
Jun 30 2020	n/a	n/a	-US$191m
Mar 31 2020	n/a	n/a	-US$376m
Dec 31 2019	US$15m	US$1m	US$447m
Sep 30 2019	n/a	n/a	US$405m
Jun 30 2019	n/a	n/a	US$306m
Mar 31 2019	n/a	n/a	US$253m
Dec 31 2018	US$9m	US$996k	US$109m
Sep 30 2018	n/a	n/a	-US$109m
Jun 30 2018	n/a	n/a	-US$102m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$16m	US$967k	-US$313m

Tazminat ve Piyasa: Herve 'nin toplam tazminatı ($USD 16.66M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.71M ).

Tazminat ve Kazançlar: Herve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Herve Hoppenot (64 yo)

10.9yrs

Görev süresi

US$16,659,526

Tazminat

Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% R$ 157.4m
Pablo Cagnoni	President and Head of Research & Development	1.6yrs	US$16.57m	0.00087% R$ 690.7k
Christiana Stamoulis	Executive VP & CFO	5.8yrs	US$5.08m	0.019% R$ 15.2m
Barry Flannelly	Executive VP & GM of North America	9.5yrs	US$4.09m	0.0062% R$ 4.9m
Steven Stein	Executive VP & Chief Medical Officer	9.8yrs	US$5.63m	0.0013% R$ 1.1m
Thomas Tray	VP of Finance	2.8yrs	Veri yok	0.0041% R$ 3.3m
Michael Morrissey	Executive VP & Head of Global Technical Operations	8.9yrs	Veri yok	0.019% R$ 14.9m
Ben Strain	Head of Investor Relations	no data	Veri yok	Veri yok
Sheila Denton	Executive VP	1.2yrs	Veri yok	0.0023% R$ 1.8m
Pamela Murphy	Vice President of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok
Paula Swain	Executive Vice President of Human Resources	22.3yrs	US$1.31m	0.030% R$ 23.8m
Vijay Iyengar	Executive VP of Global Medical Affairs	no data	US$3.30m	0.0013% R$ 1.0m

8.9yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: I1NC34 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Herve Hoppenot	CEO & Chairman	10.9yrs	US$16.66m	0.20% R$ 157.4m
Jean-Jacques Bienaime	Independent Director	9.9yrs	US$478.76k	0.0080% R$ 6.4m
Julian Baker	Independent Lead Director	23.1yrs	US$512.76k	0.14% R$ 114.9m
Otis Brawley	Independent Director	3.3yrs	US$454.76k	0.0031% R$ 2.4m
Jacqualyn Fouse	Independent Director	7.9yrs	US$466.26k	0.0073% R$ 5.8m
Edmund Harrigan	Independent Director	5yrs	US$482.26k	0.0072% R$ 5.7m
Katherine High	Independent Director	4.8yrs	US$454.76k	0.0042% R$ 3.3m
Paul Clancy	Independent Director	9.9yrs	US$479.76k	0.0086% R$ 6.8m
Susanne Schaffert	Independent Director	2.2yrs	US$444.76k	0.0015% R$ 1.2m

7.9yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: I1NC34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/20 08:18
Gün Sonu Hisse Fiyatı	2024/11/27 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Incyte Corporation 55 Bu analistlerden 23, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research

Incyte Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Recent updates

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024

Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024

Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares.

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Incyte Corporation Provides Earnings Guidance for 2024

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults

Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation

Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

Incyte Corporation Provides Revenue Guidance for the Full Year 2021

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2

Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as Treatment for Patients with Squamous Cell Anal Carcinoma

Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (Ruxolitinib) as A Treatment for Patients with Chronic Graft-Versus-Host Disease